The federal government is moving toward unified AI regulation, and healthcare organizations face significant new compliance obligations. Two major developments signal that healthcare AI, already embedded in diagnostics, drug discovery, and clinical decision support, will soon operate under a new national rulebook. The Trump administration released its National Policy Framework for Artificial Intelligence in March 2026, followed by Senator Marsha Blackburn's proposed Trump America Act, comprehensive legislation that would establish federal governance for AI systems across industries, including healthcare .

For hospitals, pharmaceutical companies, and health tech startups, the implications are substantial. These proposals would introduce new liability frameworks, mandatory bias audits, copyright-based training data requirements, and transparency obligations that directly affect high-risk, data-intensive healthcare applications. While neither proposal is final, the convergence of executive policy guidance and draft legislation signals that federal AI regulation is shifting from "if" to "when." Healthcare organizations should begin assessing how these proposals may reshape their governance programs, compliance obligations, and product development strategies now .

What Would These New Rules Actually Require Healthcare Organizations to Do?

The proposed legislation would create several new compliance layers for healthcare AI systems. The Trump America Act includes a statutory duty of care and products liability provisions that would establish a fundamentally new liability framework for AI deployment in clinical settings. This means healthcare organizations developing, deploying, or substantially modifying clinical AI systems would need to integrate these new federal requirements with existing medical malpractice, FDA compliance, and HIPAA risk management programs .

One particularly significant requirement is mandatory bias audits for high-risk AI systems. The proposed legislation would require audits to detect discrimination, with specific focus on viewpoint discrimination and discrimination based on political affiliation. These audits would apply directly to healthcare AI used in treatment recommendations, insurance eligibility decisions, or clinical resource allocation, as well as life sciences AI used in patient selection or diagnostic screening. This requirement would layer onto existing FDA expectations for AI and machine learning device performance across demographic subgroups .

How to Prepare Your Healthcare Organization for Federal AI Regulation

• Assess Liability Exposure: Review existing indemnification, quality management, and risk disclosure documentation to ensure it is robust enough to defend against AI-related claims under the proposed duty of care and products liability provisions.
• Evaluate Consent Frameworks: If your organization uses patient images, voice recordings, or other biometric data in AI development, assess whether current consent frameworks would adequately address digital replica rights that would be established under the proposed NO FAKES Act provisions.
• Implement Bias Audit Processes: Develop internal processes to conduct mandatory bias audits for high-risk AI systems, particularly those used in treatment recommendations, insurance eligibility determinations, or clinical resource allocation decisions.
• Maintain Multi-Jurisdictional Compliance Programs: Rather than assuming federal legislation will provide preemptive relief, maintain robust state compliance programs, as the proposed Act would preserve existing sectoral governance schemes including HIPAA and state health data privacy laws.
• Engage with FDA Coordination: Ensure your AI and machine learning governance programs account for the fact that FDA authority over AI-enabled medical devices would remain intact under the proposed legislation, creating a multi-track compliance environment.

The critical gap in both proposals is that neither directly addresses how federal AI policy would interact with the FDA's existing authority over AI-enabled medical devices. This represents a significant uncertainty for healthcare organizations, as the intersection of federal AI regulation and FDA oversight remains undefined. Healthcare and life sciences stakeholders should actively participate in shaping how this framework is ultimately legislated, particularly to ensure that patient safety protections are explicitly carved out from any preemption provision .

How Do These Proposals Differ, and Why Does It Matter?

The Framework and the Trump America Act take different approaches to a critical issue: preemption of state AI laws. The Framework calls for broad preemption of state AI laws that impose undue burdens, while the Act provides that it "shall not preempt any generally applicable law, such as a body of common law or a scheme of sectoral governance." This distinction is consequential for healthcare and life sciences organizations .

Under the Act's approach, existing regulatory frameworks would remain fully operative. This includes FDA oversight of AI and machine learning-enabled medical devices, HIPAA, and state medical and health data privacy laws. The Act is broader in scope than the Framework in several important respects, and organizations should be aware of both convergences and divergences between the two proposals. The preservation of "sectoral governance schemes" means FDA's existing authority over software as a medical device and clinical decision support software would remain intact, but the Act's products liability and bias audit provisions would create a multi-track compliance environment requiring organizations to navigate both federal and existing regulatory requirements simultaneously .

Another significant difference involves Section 230 of the Communications Act, which currently exempts platforms from liability for third-party content. The Trump America Act would sunset this provision. Health information platforms, telehealth providers, and patient-facing AI tools that rely on current liability protections should evaluate how this proposed change would reshape their risk profiles .

Healthcare organizations should not wait for final legislation to begin preparing. The convergence of executive policy guidance and draft legislation signals that federal AI regulation is no longer a distant possibility but an imminent reality. Organizations that begin assessing their governance programs, compliance obligations, and product development strategies now will be better positioned to adapt when these proposals move through the legislative process and ultimately become law .